Lab Reagents
Human IgG antibody Laboratories manufactures the sars cov 1 spike protein reagents distributed by Genprice. The Sars Cov 1 Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: 1 Spike
1 Spike information
SARS-CoV spike protein Antibody |
abx023143-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
Spike S1 RBD, His-tag (SARS-CoV-2) |
100687-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
100699-1 |
BPS Bioscience |
50 µg |
EUR 410 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike Trimer (S1+S2), His-tag (SARS-CoV) |
100789-1 |
BPS Bioscience |
100 µg |
EUR 450 |
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
79942-1 |
BPS Bioscience |
100 µl |
EUR 875 |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
79981-1 |
BPS Bioscience |
100 µl |
EUR 875 |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) |
100938-1 |
BPS Bioscience |
20 µg |
EUR 420 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa. |
SARS-CoV-2 Spike Peptide |
9083P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (NT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
9087P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike RBD peptide |
SARS-CoV-2 Spike Peptide |
9091P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
9095P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
Spike (SARS-CoV-2) Lentivirus |
78010-2 |
BPS Bioscience |
500 µl x 2 |
EUR 2095 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |
Spike (SARS-CoV-1) Pseudotyped Lentivirus (eGFP Reporter)-100 µl |
78633-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and these viral infections led to the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (SARS-CoV-1) pseudotyped lentivirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) pseudovirus has been validated for use with ACE2-HEK293 target cells (which overexpress ACE2; BPS Bioscience #79951). |
Sars-Cov, Spike (Middle) Recom Protein |
abx060656-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag |
E80027 |
EpiGentek |
|
|
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
79952-1 |
BPS Bioscience |
1 mg |
EUR 445 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
E80024-1 |
EpiGentek |
100 ul |
EUR 635.8 |